Buerger's disease

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instance_of gptkb:healthcare_organization
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:purple_toe_syndrome
gptkbp:affects blood vessels
gptkbp:associated_with gptkb:musician
gptkb:Raynaud's_phenomenon
thrombosis
chronic inflammatory response
gptkbp:caused_by tobacco use
gptkbp:clinical_trial ongoing research
investigating new therapies
studying disease mechanisms
gptkbp:complications amputation
gptkbp:distribution more common in Asia and the Middle East
gptkbp:first_described_by Leo Buerger
gptkbp:historical_significance influenced vascular medicine
named after Leo Buerger
recognized in the early 20th century
https://www.w3.org/2000/01/rdf-schema#label Buerger's disease
gptkbp:is_known_for thromboangiitis obliterans
gptkbp:is_popular_in more common in men
typically diagnosed in young adults
gptkbp:is_protected_by quitting smoking
managing stress
avoiding tobacco products
gptkbp:research_focus risk factors
treatment options
pathophysiology
gptkbp:risk_factor smoking
genetic predisposition
autoimmune conditions
gptkbp:social_responsibility ultrasound
biopsy
clinical examination
angiography
more prevalent in certain ethnic groups
rare in non-smokers
gptkbp:symptoms numbness
gangrene
tingling
pain in limbs
cold sensitivity
ulcers on fingers
gptkbp:treatment gptkb:hospital
stem cell therapy
medications
physical therapy
anticoagulants
pain management
smoking cessation
hyperbaric oxygen therapy
vasodilators